Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes
Jasmine C. Wong, Victoria Bryant, Tamara Lamprecht, Jing Ma, Michael Walsh, Jason Schwartz, Maria del pilar Alzamora, Charles G. Mullighan, Mignon L. Loh, Raul Ribeiro, James R. Downing, William L. Carroll, Jeffrey Davis, Stuart Gold, Paul C. Rogers, Sara Israels, Rochelle Yanofsky, Kevin Shannon, Jeffery M. Klco
Jasmine C. Wong, Victoria Bryant, Tamara Lamprecht, Jing Ma, Michael Walsh, Jason Schwartz, Maria del pilar Alzamora, Charles G. Mullighan, Mignon L. Loh, Raul Ribeiro, James R. Downing, William L. Carroll, Jeffrey Davis, Stuart Gold, Paul C. Rogers, Sara Israels, Rochelle Yanofsky, Kevin Shannon, Jeffery M. Klco
View: Text | PDF
Research Article Hematology

Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes

  • Text
  • PDF
Abstract

Germline SAMD9 and SAMD9L mutations cause a spectrum of multisystem disorders that carry a markedly increased risk of developing myeloid malignancies with somatic monosomy 7. Here, we describe 16 siblings, the majority of which were phenotypically normal, from 5 families diagnosed with myelodysplasia and leukemia syndrome with monosomy 7 (MLSM7; OMIM 252270) who primarily had onset of hematologic abnormalities during the first decade of life. Molecular analyses uncovered germline SAMD9L (n = 4) or SAMD9 (n = 1) mutations in these families. Affected individuals had a highly variable clinical course that ranged from mild and transient dyspoietic changes in the bone marrow to a rapid progression of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with monosomy 7. Expression of these gain-of-function SAMD9 and SAMD9L mutations reduces cell cycle progression, and deep sequencing demonstrated selective pressure favoring the outgrowth of clones that have either lost the mutant allele or acquired revertant mutations. The myeloid malignancies of affected siblings acquired cooperating mutations in genes that are also altered in sporadic cases of AML characterized by monosomy 7. These data have implications for understanding how SAMD9 and SAMD9L mutations contribute to myeloid transformation and for recognizing, counseling, and treating affected families.

Authors

Jasmine C. Wong, Victoria Bryant, Tamara Lamprecht, Jing Ma, Michael Walsh, Jason Schwartz, Maria del pilar Alzamora, Charles G. Mullighan, Mignon L. Loh, Raul Ribeiro, James R. Downing, William L. Carroll, Jeffrey Davis, Stuart Gold, Paul C. Rogers, Sara Israels, Rochelle Yanofsky, Kevin Shannon, Jeffery M. Klco

×

Figure 2

SAMD9L H880Q mutation in MLSM7 family 1.

Options: View larger image (or click on image) Download as PowerPoint

SAMD9L H880Q mutation in MLSM7 family 1.
(A) Pedigree showing the germl...
(A) Pedigree showing the germline SAMD9L mutation (red font) in the father (1P) and patients 1A and 1B, as well as secondary somatic mutations identified in their AML bone marrows (black font). Squares indicate male family members, circles female members. Unaffected individuals are indicated with open symbols, unaffected mutation carriers are denoted with black dots, affected individuals with a clinical history of monosomy 7 are shown with filled symbols, and symbols with a slash denote deceased individuals. Arrow indicates the proband. (B) Sequencing data from the father (1P) showing the number of individual amplicons with normal sequence (left), those with the p.H880Q mutation only (middle), and those with the p.H880Q and p.Q569P substitutions in cis (right). The p.Q569P second-site mutation was only detected in the context of the p.H880Q variant and accounted for over 80% of mutant transcripts. (C) EdU cell cycle results showing that 293T cells expressing SAMD9L p.H880Q exhibit a cell cycle arrest phenotype compared with cells expressing the normal SAMD9L protein. This defect is partially corrected by the second-site p.Q569P substitution detected in 1P. Percentages of cells in the S phase of the cell division cycle were compared using 1-way ANOVAs with repeated measures followed by Tukey’s post hoc multiple-comparisons test; significance was based on α = 0.05 (n = 3). ****P < 0.0001. n.s., not significant. Individual data points, and mean ± SD are shown. Data representative of 3 experiments completed in triplicate.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts